Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer

Urology

Volumn 77, Issue 4, 2011, Pages 986-990

  Zelefsky, Michael J ^a   Yamada, Yoshiya ^a   Pei, Xin ^a   Hunt, Margie ^a   Cohen, Gilad ^a   Zhang, Zhigang ^a   Zaider, Marco ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RELAPSE; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM INJURY; URINARY TRACT INJURY;

EID: 79953869316     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.07.539     Document Type: Article

References (22)

1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)
3. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(Pt. 1):1415-1419. (Pubitemid 44307191)
4. Kupelian PA, Ciezki J, Reddy CA, et al. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:16-22. (Pubitemid 351491401)
5. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157-164. (Pubitemid 44080699)
6. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1(T2) prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333. (Pubitemid 46108308)
7. 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology. 2009;73:860-867.
8. Hinnen KA, Jan JB, van Roermund JG, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;76:1433-1438.
9. 125iodine brachytherapy for prostate cancer. J Urol. 2005;173:803-807.
10. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522. (Pubitemid 29075237)
11. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65-70. (Pubitemid 44959499)
12. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929-943.
13. Pieters BR, van de Kamer JB, van Herten YR, et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol. 2008;88:46-52.
14. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239-2247. (Pubitemid 46801553)
15. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:421-432.
16. Klein EA, Ciezki J, Kupelian PA, et al. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol. 2009;27:67-71.
17. Wyler SF, Engeler DS, Seelentag W, et al. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int. 2009;82:17-23.
18. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23:2772-2780. (Pubitemid 46179467)
19. Tward JD, Lee CM, Pappas LM, et al. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer. 2006;107:2392-2400. (Pubitemid 44748522)
20. Fang FM, Wang YM, Wang CJ, et al. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol. 2008;38:474-479.
21. Wong WW, Vora SA, Schild SE, et al. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer. 2009;115:5596-5606.
22. (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008;71:338-345.